Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06346899
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-03-29
Brief Title:
A Study of Lanadelumab Takhzyro and Icatibant Firazyr in Persons With HAE in China
Sponsor:
Takeda
Organization:
Takeda
Study Overview
Official Title:
The Real-World Effectiveness and Safety of Lanadelumab Takhzyro and Icatibant Firazyr for Hereditary Angioedema An Observational Study in China
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema HAE attacks in persons of 12 years and older It has also approved icatibant to treat acute HAE attacks in persons 2 years and older
One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab such as the dose and how often it needs to be given reasons for stopping the treatment with lanadelumab and how long it was taken until stopping Participants will be treated by their doctors according to routine medical practice Only data already available in the medical records of the participants will be reviewed and collected during this study
One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab such as the dose and how often it needs to be given reasons for stopping the treatment with lanadelumab and how long it was taken until stopping Participants will be treated by their doctors according to routine medical practice Only data already available in the medical records of the participants will be reviewed and collected during this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None